What Enliven Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 14 | 76 |
| Total trades | 24 | 103 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 196,795 | 471,593 |
| Disposed | 204,849 | 1,803,926 |
| Net activity | −8,054 | −1,332,333 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Oct 19 | Open-market sale · S | −6,018 | $38.48 | −$232K | 38,000 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Oct 19 | Exercise / conversion · M | +6,018 | $14.85 | +$89.4K | 44,018 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Oct 19 | Open-market sale · S | −5,000 | $38.47 | −$192K | 25,000 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Oct 19 | Exercise / conversion · M | +5,000 | $2.48 | +$12.4K | 30,000 |
| Garland J. Scott | Director | Oct 01 | Open-market sale · S | −13,000 | $46.67 | −$607K | 0 |
| Garland J. Scott | Director | Oct 01 | Exercise / conversion · M | +13,000 | $15.47 | +$201K | 13,000 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sep 17 | Open-market sale · S | −289 | $51.49 | −$14.9K | 38,000 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sep 17 | Open-market sale · S | −2,194 | $50.72 | −$111K | 38,289 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sep 17 | Open-market sale · S | −3,535 | $50.03 | −$177K | 40,483 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sep 17 | Exercise / conversion · M | +3,982 | $14.85 | +$59.1K | 44,018 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Sep 17 | Open-market sale · S | −240 | $51.48 | −$12.4K | 25,000 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Sep 17 | Open-market sale · S | −1,844 | $50.71 | −$93.5K | 25,240 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Sep 17 | Open-market sale · S | −2,916 | $50.03 | −$146K | 27,084 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Sep 17 | Exercise / conversion · M | +5,000 | $2.48 | +$12.4K | 30,000 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Aug 17 | Open-market sale · S | −1,388 | $59.35 | −$82.4K | 40,036 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Aug 17 | Open-market sale · S | −4,630 | $58.35 | −$270K | 41,424 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Aug 17 | Open-market sale · S | −1,100 | $59.35 | −$65.3K | 25,000 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Aug 17 | Open-market sale · S | −3,900 | $58.37 | −$228K | 26,100 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Aug 17 | Exercise / conversion · M | +5,000 | $2.48 | +$12.4K | 30,000 |
| Derynck Mika K | Director | Aug 04 | Open-market sale · S | −158,795 | $60.21 | −$9.56M | 0 |
Loading...